Clinical Trials Directory

Trials / Completed

CompletedNCT00456040

Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant

Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation

Status
Completed
Phase
Study type
Observational
Enrollment
25 (planned)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.

Detailed description

Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation. The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased. Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant. We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.

Conditions

Timeline

Start date
2007-03-01
Completion
2007-03-01
First posted
2007-04-04
Last updated
2007-04-04

Source: ClinicalTrials.gov record NCT00456040. Inclusion in this directory is not an endorsement.

Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant (NCT00456040) · Clinical Trials Directory